In a report released on October 17, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Nuvalent (NUVL – Research Report), with a price target of $100.00. The company’s shares closed yesterday at $53.05.
According to TipRanks, Canino is an analyst with an average return of -30.2% and a 21.18% success rate. Canino covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Arvinas Holding Company, and ALX Oncology Holdings.
In addition to Stifel Nicolaus, Nuvalent also received a Buy from BMO Capital’s Etzer Darout in a report issued yesterday. However, on October 16, Leerink Partners assigned a Hold rating to Nuvalent (NASDAQ: NUVL).
See Insiders’ Hot Stocks on TipRanks >>
Based on Nuvalent’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $29.09 million. In comparison, last year the company had a GAAP net loss of $18.47 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvalent (NUVL) Company Description:
Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
Read More on NUVL:
